Denosumab Treatment Does Not Halt Progression of Bone Lesions in Multicentric Carpotarsal Osteolysis Syndrome

ABSTRACT Here we report the use of denosumab, a monoclonal antibody against receptor activator of nuclear factor κB ligand (RANKL), as monotherapy for multicentric carpotarsal osteolysis syndrome (MCTO) in an 11.5‐year‐old male with a heterozygous missense mutation in MAFB (c.206C>T; p.Ser69Leu). We...

Полное описание

Библиографические подробности

Главные авторы:	Melissa A. Lerman, Michael Francavilla, Lindsay Waqar‐Cowles, Michael A. Levine
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Oxford University Press 2023-05-01
Серии:	JBMR Plus
Предметы:	DENOSUMAB MafB MULTICENTRIC CARPOTARSAL OSTEOLYSIS SYNDROME RANKL‐INHIBITOR
Online-ссылка:	https://doi.org/10.1002/jbm4.10729
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!